Percutaneous drug-eluting balloon angioplasty to treat dialysis access stenosis. Massara M,Finocchiaro P,Volpe A,et al. Seminars in Vascular Surgery . 2017Massara M,Finocchiaro P,Volpe A,et al.Percutaneous drug-eluting balloon angioplasty to treat dialysis access stenosis[J].Semin Vasc Surg,2017,...
Kayssi A, Al-Atassi T, Oreopoulos G, Roche-Nagle G, Tan KT, Rajan DK. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs. Cochrane Database Syst Rev 2016;8:CD011319....
AngioplastyStentDrug eluting stentPeripheral arterial disease is one of the manifestations of systemic atherosclerosis. In the last decade, remarkable technological advances, especially in the stent area, have shifted revascularization strategies from traditional open surgical approaches toward less morbide ...
The balloon technology relies on the concept of targeted drug delivery, which helps in the rapid healing of the vessel wall and prevents the proliferation of smooth muscle cells. Drug eluting balloon is a semi-compliant angioplasty balloon, coated with anti-proliferative medicine. The medicine is ...
Percutaneous transluminal balloon angioplasty (PTA) is currently the predominant nonsurgical intervention, but data from the ACHILLES trial indicate that sirolimus-eluting stent implantation (SES) is a suitable alternative therapeutic approach in these patients....
The first, LEVANT 2 , was designed to look at 12-month outcomes in 476 patients with stenotic femoropopliteal arteries randomized 2:1 to either a drug-eluting balloon (Lutonix, Bard) or standard balloon angioplasty; earlier this month, the company announced top-line results, saying the trial ...
(a) A typical MAC cell; (b) IBM nodes demarcation and interpolation; (c) Interstitial velocity-vector (not to scale); (d) Sirolimus release profile during balloon angioplasty. Full size image The velocity-vector after angioplasty, obtained by solving the Eqs. (1and2), is displayed in Fig...
Paclitaxel-coated balloon angioplasty for de novo coronary lesions: a long-term follow-up study. Minerva Cardioangiol. 2016;64:15–22. PubMed Google Scholar Uhlemann M, Möbius-Winkler S, Adam J, et al. The Leipzig prospective drug-eluting balloon-registry—outcome of 484 consecutive ...
Drug-coated 0.035" angioplasty balloons Specialty balloons Stellarex drug-coated balloon featuring EnduraCoat technology comprising hybrid coating, Polyethylene glycol (PEG) excipient and 2µg/mm² low drug dose. Proven safety and efficacy in SFA. ...
Drug-eluting stents (DES) have revolutionized interventional cardiology. The first bare-metal stents successfully prevented abrupt artery closure and reduced the likelihood of clinical restenosis compared with balloon angioplasty. They were, however, limited by the frequent occurrence of restenosis owing to...